<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03889145</url>
  </required_header>
  <id_info>
    <org_study_id>ID-TAH-1301</org_study_id>
    <nct_id>NCT03889145</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Drug-drug Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, 3-way Crossover Study to Evaluate the Drug-drugs Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, single dose, 3-way crossover study to evaluate the drug-drugs
      interaction between Telmisartan, Amlodipine and Hydrochlorothiazide in healthy male
      volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2013</start_date>
  <completion_date type="Actual">February 19, 2014</completion_date>
  <primary_completion_date type="Actual">February 19, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>t1/2</measure>
    <time_frame>Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>CL/F</measure>
    <time_frame>Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Telmisartan, Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan, Amlodipine, Hydrochlorothiazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 80mg</intervention_name>
    <description>Telmisartan 80mg</description>
    <arm_group_label>Telmisartan, Amlodipine</arm_group_label>
    <arm_group_label>Telmisartan, Amlodipine, Hydrochlorothiazide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine10mg</intervention_name>
    <description>Amlodipine 10mg</description>
    <arm_group_label>Telmisartan, Amlodipine</arm_group_label>
    <arm_group_label>Telmisartan, Amlodipine, Hydrochlorothiazide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Hydrochlorothiazide 25mg</description>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
    <arm_group_label>Telmisartan, Amlodipine, Hydrochlorothiazide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers aged 20 to 55 years

          -  Subjects who have 17.5 ~ 30.5 kg/m2 body mass index (BMI) and body weight that is more
             than 55kg

          -  Subjects who have no congenital or chronic disease within the last 3 years and have no
             pathological symptoms or findings as a result of medical examination.

          -  Suitable subject who is determined by laboratory tests such as hematology tests, blood
             chemistry, urinalysis test according to the characteristics of the drug and screening
             tests such as electrocardiography(ECG) test.

          -  Subject who fully understand the clinical trials after in-depth explanation given
             prior to the clinical study, decided to join the clinical trials by their will and
             signed consent form which approved by Chonbuk National University Hospital
             Institutional Review Board(IRB).

        Exclusion Criteria:

          -  Subjects who have a history of blood, kidneys, endocrine, respiratory,
             gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or
             allergic diseases that is clinically significant (Except untreated asymptomatic
             seasonal allergies at the time of administration)

          -  Subjects who have a history of gastrointestinal disease or gastrointestinal surgery
             which can affect drug absorption.

          -  Subjects who drink Alcohol &gt; 210g/week within 6 months prior to the screening.

          -  Subjects who involved in other clinical trials within two months before the first dose
             medication characters.

          -  Subjects who show Systolic Blood Pressure ≤100 or ≥150 mmHg or Diastolic Blood
             Pressure ≤60 or ≥100 mmHg at screening

          -  Subjects who had alcohol or drug abuse within one year before the screening

          -  Subjects who took medication of drug-metabolizing enzymes that are known to
             significantly induce or inhibit within 30 days

          -  Subjects who smoke 20 cigarettes or more a day

          -  Subjects who take medicine within 10 days before the first investigational product
             administration.

          -  Subject who done the whole blood donation within two months or component blood
             donation within 1 month within 1 month prior to the first dosing.

          -  Subject who can increase risk due to clinical test and administration of drugs or has
             severe grade / chronic medical, mental condition or abnormal laboratory result that
             may interfere with the analysis of test results.

          -  Subjects with serious history of hypersensitivity or allergy to investigational
             product.

          -  Subjects with severe hepatic impairment or Gallbladder Disease.

          -  Subject with hereditary angioedema or a history of angioedema when treated with
             ACE(Angiotensin-Converting enzyme) inhibitor or ARB(Angiotensin II Receptor Blocker)
             therapy

          -  Subjects who take combination medication with aliskiren in Diabetic patient or
             moderate to severe renal insufficient subjects (glomerular filtration
             rate&lt;60mL/min/1.73m2)

          -  Subjects with severe hepatic impairment

          -  Subjects who have severe aortic stenosis

          -  Subjects with acute or severe renal failure

          -  Subjects with hyponatremia or hypokalemia

          -  Subjects with Addison's disease

          -  Subjects with hypercalcemia

          -  Subjects who have galactose intolerance, Lapp lactase deficiency or glucose-galactose
             malabsorption

          -  Subjects who are unwilling or unable to comply with the Lifestyle guidelines described
             in this protocol

          -  Subject who are inadequate for this study to participate judged by investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

